

## PRESS RELEASE

# Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar

Hansa Biopharma to participate in several leading global healthcare conferences in September

**Lund, Sweden August 31, 2021** Hansa Biopharma AB "Hansa", (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that the Company's management team will present at the following upcoming investor conferences during September 2021:

- Erik Penser Access Minibolags dag, Malmö Tuesday August 31, 2021 at 17:15 (CET)
- Pareto Securities Health Care Conference on Thursday September 2 2021, at 13:10 (CET)
- Redburn Gene Therapy Virtual Summit Tuesday September 7, 2021 at 17:35 (CET)/16:35 (BST)
- H.C. Wainwright Global Investment Conference Monday September 13, 2021 at 13:00 (CET)/ 7:00am (EST)
- Morgan Stanley Global Healthcare Conference Tuesday September 14, 2021 (1x1 meetings only)
- Bank of America Merrill Lynch Healthcare Conference Thursday September 16, 2021 (1x1 meetings only)
- Danske Bank Life Science Seminar "Platform companies" Friday September 17, 2021 at 13:00 (CET)

A link to the applicable presentations and webcasts will be available under the "Events & Presentations" section on the Company's website at [www.hansabiopharma.com](http://www.hansabiopharma.com).

### Calendar

Aug 31, 2021	Erik Penser Access, Malmö
Sep 2, 2021	Pareto Healthcare Conference, Stockholm (virtual)
Sep 7, 2021	Redburn Gene Therapy Virtual Summit
Sep 10+13, 2021	HC Wainwright Annual Global Investment Conference (virtual)
Sep 14, 2021	Morgan Stanley Global Healthcare Conference (virtual)
Sep 16, 2021	BAML Global Healthcare Conference (virtual)
Sep 17, 2021	Danske Bank Life Science event "Platform companies" (virtual)
Sep 30, 2021	Erik Penser Temadag Sär läkemedel, Stockholm
Oct 21, 2021	<b>Interim report for Jan-Sep 2021</b>
Oct 22+26, 2021	Kempen NDRS EU/US (virtual)
Nov 10, 2021	Ökonomisk Ugebrev Life Science Conference, Copenhagen
Nov 16-18, 2021	Jefferies London Healthcare Conference (virtual)
Nov 25, 2021	Erik Penser Banks Bolagsdag, Stockholm/virtual
Dec 1-2, 2021	Geneva MidCap Event (virtual)
Jan 9-13, 2022	JP Morgan week, San Francisco
Feb 3, 2022	<b>Year-End report for Jan - Dec 2021</b>
April 7, 2022	<b>Annual Report 2021</b>
April 21, 2022	<b>Interim report for Jan - Mar 2022</b>

### About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

--ENDS--

#### For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: [klaus.sindahl@hansabiopharma.com](mailto:klaus.sindahl@hansabiopharma.com)

Katja Margell, *Head of Corporate Communications*

M: +46 (0) 768-198 326

E: [katja.margell@hansabiopharma.com](mailto:katja.margell@hansabiopharma.com)